Abstract:Background: with AML who obtain first complete remission (CR) are subsequently treated with post-remission treatment, including chemotherapy or hematopoietic stem cell transplantation (HSCT). Suitable post-remission treatment in patients with intermediate-risk acute myeloid leukemia (AML) is remaining investigation.Objectives: To retrospectively investigatethe value of allo-HSCT in the patients with intermediate-risk AML.Patients and Methods: From August 2010 to January 2016, newly diagnosed adultpatients (15 to 55 years old) with AML were consecutivelyenrolled in a prospective trial (ChiCTR-TRC-10001202). Patients were assigned HAD containing conventional dose of cytarabine (homoharringtonine, cytarabine (Ara-c), and daunorubicin) induction therapy (Ara-C 100mg/m2, d1-7) or HAD containing intermediate dose Ara-c (Ara-C 100mg/m2, d1-4, 1.0g/m2, q12h, d5-7). All patients who achieved CR received either high dose Ara-c or intermediate dose Ara-c plus anthracyclines. Allo-HSCT was based on therapeutic responseand patientsu0027 intention. Patients received 6 courses of consolidation therapy if they did not receive HSCT. Minimal residual disease (MRD) was analyzed by multi-color flow cytometry after induction and consolidation therapy.Results: 181 enrolled patients were intermediate-risk AML (median age 36 years old). The median follow-up was 15.5 (0.5-67.9) months. One patient was lost to follow-up after induction, 180 patients were evaluated. 128 patients (71.1%) achieved CR after one induction cycle, 7 patients (3.9%) were early death, and 45 patients (25.0%) did not achieve CR. Forty patients received allo-HSCT, 33 of them were in CR1. The median time from diagnosis to transplantation was 6.5(3.9-16.0) months. Three years overall survival (OS) of transplantation group was higher than that of chemotherapy group (78.0% vs 48.0%, P = 0.000). Three years relapse-free survival (RFS) was 42.0% and 45.0% for patients in transplantation group and chemotherapy group, respectively (P = 0.196).However, taking transplantation time into account, the outcome was different. If the median transplantation time (6.5 months) was defined as cut-off value, there is no statistically difference of 3 years OS (77.0% vs 69.0%, P =0.182) and 3 years RFS (42.0% vs 53.0%, P =0.320) between transplantation and chemotherapy groups in the patients without relapse within 6.5 months. Twenty-one patients relapsed within 6.5 months, only one of them proceeded to allo-HSCT, and 1 year OS was 29.0%. For 45 patients who did not achieve CR after one induction cycle, 3 years OS was much better by allo-HSCT as compared with chemotherapy (85.0% vs22.0%, P = 0.008).In order to evaluate prognosis earlier, we analyzed MRD by flow cytometry after induction, first and second consolidation cycles in those achieving CR after one induction cycle. The patients with once or more MRD positive of three time points had significantly inferior 6 months RFS than those with continuous MRD negative (61.0% vs 92.0%, P = 0.005). Similar trend was observed on 1 year RFS (46.0% vs 76.0%, P = 0.005).Conclusion: According to the actual treatment, the OS of the patients with intermediate-risk AML was improved by allo-HSCT. When transplantation time was considered in the analysis, there was no difference between allo-HSCT and chemotherapy in survival. The patients with poor early response to chemotherapy (those did not achieve CR after one induction cycle) really benefited from allo-HSCT. The patients without continuous MRD negative after induction, first and second consolidation cycles trended to be early relapse, they might be another subgroup benefiting from allo-HSCT.Acknowledgments: This study was supported, in part, by State Key Program of National Natural Science of China (81430004), Foundation for Innovative Research Groups of the NaturalScience Foundation of China (81421002).Disclosures No relevant conflicts of interest to declare.

Autologous Stem Cell Transplantation Is A Viable Postremission Therapy For Intermediate-Risk Acute Myeloid Leukemia In First Complete Remission In The Absence Of A Matched Identical Sibling: A Meta-Analysis

Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies.

Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission.

Comparison of Autologous Stem Cell Transplantation Versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.

Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials.

Autologous Stem Cell Transplantation in Adult Patients with Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission and No Detectable Minimal Residual Disease. A Comparative Retrospective Study with Haploidentical Transplants of the Global Committee and the ALWP of the EBMT

P1391: COMPARISON OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION

The Impact Of Allogeneic Hematopoietic Stem-Cell Transplantation On Outcome Of The Patients With Intermediate-Risk Acute Myeloid Leukemia

Comparison of Allogeneic Hematopoietic Cell Transplantation Versus Chemotherapy in Patients with Acute Myeloid Leukemia in First Remission

Chemotherapy or Allogeneic Stem Cell Transplantation As Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis

Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Promyelocytic Leukemia: Results of a Systematic Review and Meta-Analysis

New Approaches In Allogenic Transplantation In Aml

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.

Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy As Postremission Treatment of Children with Intermediate-risk Acute Myeloid Leukemia in First Complete Remission.

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis

High-dose Idarubicin Plus Busulfan As Conditioning Regimen to Autologous Stem Cell Transplantation: Promising Post-Remission Therapy for Acute Myeloid Leukemia in First Complete Remission?

Allogeneic Hematopoietic Stem Cell Transplantation for Intermediate-Risk Acute Myeloid Leukemia in the First Remission: Outcomes Using Haploidentical Donors Are Similar to Those Using Matched Siblings.

HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia: Long-Term Follow-Up

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.